Erythropoietin and retinopathy of prematurity

Early Human Development

Volumn 87, Issue SUPPL., 2011, Pages

  Romagnoli, C ^a   Tesfagabir, M G ^a   Giannantonio, C ^a   Papacci, P ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Erithropoietin; Retinopathy of prematurity; Vascular growth factors

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; ARTIFICIAL VENTILATION; BLOOD TRANSFUSION; ERYTHROPOIESIS; GENETIC PREDISPOSITION; GESTATIONAL AGE; HUMAN; NEUROPROTECTION; NONHUMAN; RETROLENTAL FIBROPLASIA; VERY LOW BIRTH WEIGHT;

AGE FACTORS; ERYTHROPOIETIN; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; RECOMBINANT PROTEINS; RETINOPATHY OF PREMATURITY; SIGNAL TRANSDUCTION;

EID: 79951812027     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2011.01.027     Document Type: Article

References (43)

1. Maier R.F., Obladen M., Muller-Hansen I., Kattner E., Merz U., Arlettaz R., et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000g. J Pediatr 2002, 141:8-15.
2. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003, 228:1-14.
3. Aher S.M., Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, 3:CD004865.
4. Ohlsson A., Aher S. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, 3:CD004863.
5. Zuppa A.A., Alighieri G., Calabrese V., Visintini F., Cota F., Carducci C., et al. Recombinant human erythropoietin in the prevention of late anemia in intrauterine transfused neonates with Rh-isoimmunization. J Pediatr Hematol Oncol 2010, 32:e95-e102.
6. Dame C., Juul S., Christensen R.D. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 2001, 79:228-235.
7. Gassmann M., Heinicke K., Soliz J., Ogunshola O.O. Nonerythroid. functions of erythropoietin. Adv Exp Med Biol 2003, 543:323-330.
8. Jelkmann W., Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004, 83:673-686.
9. Fandrey J. A cordial affair: erythropoietin and cardioprotection. Cardiovasc Res 2006, 72:1-2.
10. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340-1346.
11. Jaquet K., Krause K., Tawakol-Khodai M., Geidel S., Kuck K.H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002, 228:1-14.
12. Juul S.E., Yachnis A.T., Christensen R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998, 52:235-249.
13. Wang G.L., Semenza G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993, 90:4304-4308.
14. Chen J., Smith L.E.H. Retinopathy of prematurity. Angiogenesis 2007, 10:133-140.
15. Blair B.M., O'Halloran H.S., Pauly T.H., Stevens J.L. Decreased incidence of retinopathy of prematurity, 1995-1997. J AAPOS 2001, 5:118-122.
16. Bullard S.R., Donahue S.P., Feman S.S., Sinatra B.B., Walsh W.F. The decreasing incidence and severity of retinopathy of prematurity. J AAPOS 1999, 3:46-52.
17. Giannantonio C., Papacci P., Molle F., Lepore D., Gallini F., Romagnoli C. An epidemiologic analysis of retinopathy of prematurity over 10years. J Pediatr Ophthalmol Strabismus 2008, 45:162-167.
18. Todd D.A., Wright A., Smith J. The NICUS Group. Severe retinopathy of prematurity in infants ,30weeks' gestation in New South Wales and the Australian Capital Territory from 1992 to 2002. Arch Dis Child Fetal Neonatal Ed 2007, 92:F251-F.
19. Pierce E.A., Foley E.D., Smith L.E.H. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996, 114:1219-1228.
20. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995, 1:1024-1028.
21. Hellstrom A., Perruzzi C., Ju M., Engstrom E., Hard A.L., Liu J.L., et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001, 98:5804-5808.
22. Hellstrom A., Engstrom E., Hard A.-L., Albertsson-Wikland K., Carlsson B., Niklasson A., et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003, 112:1016-1020.
23. Smith L.E.H. Pathogenesis of retinopathy of prematurity. Semin Neonatol 2003, 8:469-473.
24. Romagnoli C. Risk factors and growth factors in ROP. Early Hum Dev 2009, 85(10 suppl):S79-S82.
25. Romagnoli C., Zecca E., Gallini F., Girlando P., Zuppa A.A. Do recombinant human erythropoietin (rhEPO) and Iron supplementation increase the risk of retinopathy of prematurity?. Eur J Pediatr 2000, 159:627-628.
26. Saugstad O.D. Oxygen toxicity in the neonatal period. Acta Paediatr Scand 1990, 79:881-892.
27. Sullivan J.L. Retinopathy of prematurity and iron: a modification of the oxygen hypothesis. Pediatrics 1986, 78:1171-1172.
28. Manzoni P., Maestri A., Gomirato G., Takagi H., Watanabe D., Matsui S. Erythropoietin as a retinal angiogenic factor. N Engl J Med 2005, 353:2190-2191.
29. Aher S.M., Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, 3:CD004868.
30. Brown M.S., Baron A.E., France E.K., Hamman R.F. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J AAPOS 2006, 10:143-149.
31. Suk K.K., Dunbar J.A., Liu A., Daher N.S., Leng C.K., Leng J.K., et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS 2008, 12:233-238.
32. Fauchere J.-C., Dame C., Vonthein R., Koller B., Arri S., Wolf M., et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008, 122:375-382.
33. Slusarski J.D., McPherson R.J., Wallace G.N., Juul S.E. High-dose erythropoietin does not exacerbate retinopathy of prematurity in rats. Pediatr Res 2009, 66:625-630.
34. Chen J., Connor K.M., Aderman C.M., Smith L.E. Erythrpoietin deficiency decreases vascular stability in mice. J Clin Invest 2008, 118:526-533.
35. Carlini R.G., Reyes A.A., Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995, 47:740-745.
36. Ribatti D., Presta M., Vacca A., Ria R., Giuliani R., Dell'Era P., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 3:2627-2636.
37. Watanabe D., Kiyoshi S., Matsui S., Kurimoto M., Kiryu J., Kita M., et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005, 353:782-792.
38. Grimm C., Wenzel A., Acar N., Keller S., Seeliger M., Gassmann M. Hypoxic preconditioning and erythropoietin protect retinal neurons from degeneration. Adv Exp Med Biol 2006, 588:119-131.
39. Becerra S.P., Amaral J. Erythropoietin-an endogenous retinal survival factor. N Engl J Med 2002, 347:1968-1970.
40. Patel S., Rowe M.J., Winters S.A., Ohls R.K. Elevated erythropoietin mRNA and protein concentrations in the developing human eyes. Pediatr Res 2008, 63:394-397.
41. Sato T., Kusaka S., Shimojo H., Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009, 116:1599-1603.
42. Chen J., Smith L.E.H. A double-edged sword: erythropoietin eyed in retinopathy of prematurity. Ophthalmology 2009, 116:221-222.
43. Sears J.E. Stimulating angiogenesis to prevent ischemic retinopathy. Ophthalmology 2009, 116:1597-1598.